Current Infectious Disease Reports

, Volume 5, Issue 1, pp 41–42 | Cite as

The development of miltefosine for the treatment of visceral and cutaneous Leishmaniasis

  • Richard D. Pearson
Clinical Trials Report


  1. 1.
    Pearson RD, Sousa AQ, Jeronimo SMB: Leishmania species: visceral (kala-azar), cutaneous and mucosal leishmaniasis. In Principles and Practice of Infectious Diseases, 5th edn. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone; 2000:2831–2845.Google Scholar
  2. 2.
    Croft SL, Neal RL, Pendergast W, Chan JH: The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987, 36:2633–2636.PubMedCrossRefGoogle Scholar
  3. 3.
    Jha TK, Sundar S, Thakur CP, et al.: Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999, 341:1795–1800.PubMedCrossRefGoogle Scholar
  4. 4.
    Sundar S, Rosenkaimer F, Makharia MK, et al.: Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998, 352:1821–1823.PubMedCrossRefGoogle Scholar
  5. 5.
    Sundar S, Gupta LB, Makharia MK, et al.: Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999, 93:589–597.PubMedCrossRefGoogle Scholar
  6. 6.
    Sundar S, Makharia A, More DK, et al.: Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000, 31:1110–1113.PubMedCrossRefGoogle Scholar
  7. 7.
    Soto J, Toledo J, Gutierrez P, et al.: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001, 33:E57-E61.PubMedCrossRefGoogle Scholar
  8. 8.
    Sundar S, Jha TK, Thakur CP, et al.: Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002, 347:1739–1746.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Richard D. Pearson

There are no affiliations available

Personalised recommendations